You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

coformulation

Showing 1 - 25 of 25
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Helminthes; Infestation, Intestinal Trial in Nairobi (Albendazole and Ivermectin fixed dose coformulation, Albendazole)

Recruiting
  • Helminthes; Infestation, Intestinal
  • Albendazole and Ivermectin fixed dose coformulation
  • Albendazole
  • Bahir Dar, Ethiopia
  • +2 more
Dec 16, 2022

Bladder Cancer Trial (pembrolizumab)

Active, not recruiting
  • Bladder Cancer
  • Pembrolizumab
  • +2 more
  • (no location specified)
Oct 11, 2022

Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

Not yet recruiting
  • Solid Tumor
  • +2 more
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Sep 7, 2023

Tumors Trial (vibostolimab, pembrolizumab, pemetrexed)

Active, not recruiting
  • Neoplasms
  • vibostolimab
  • +6 more
  • (no location specified)
Apr 22, 2022

Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (biological, drug, other)

Recruiting
  • Metastatic Castration-Resistant Prostate Cancer
  • Pembrolizumab 200 mg
  • +11 more
  • Los Angeles, California
  • +30 more
Aug 12, 2022

Esophageal Squamous Cell Carcinoma (ESCC) Trial in Japan, Taiwan (Pembrolizumab, Coformulation favezelimab/pembrolizumab,

Recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Pembrolizumab
  • +5 more
  • Milan, Lombardia, Italy
  • +13 more
Jan 3, 2023

Metastatic Non Small Cell Lung Cancer Trial in Worldwide (Pembrolizumab/Vibostolimab coformuation, Docetaxel, Placebo)

Active, not recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Pembrolizumab/Vibostolimab coformuation
  • +2 more
  • Los Angeles, California
  • +94 more
Jan 4, 2023

Small Cell Lung Carcinoma Trial in Worldwide (coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830)

Active, not recruiting
  • Small Cell Lung Carcinoma
  • coformulation pembrolizumab/quavonlimab
  • +3 more
  • Gilbert, Arizona
  • +46 more
Jan 2, 2023

Tumors Trial in Worldwide (MK-4830, Pembrolizumab, Carboplatin)

Recruiting
  • Neoplasms
  • San Francisco, California
  • +31 more
Dec 23, 2022

Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +5 more
  • Los Angeles, California
  • +39 more
Jan 25, 2023

NSCLC Trial in Worldwide (biological, drug, radiation)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • pembrolizumab/vibostolimab
  • +7 more
  • Hollywood, Florida
  • +29 more
Aug 22, 2022

Carcinoma, Renal Cell Trial in Worldwide (Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan)

Recruiting
  • Carcinoma, Renal Cell
  • Pembrolizumab
  • +5 more
  • New Haven, Connecticut
  • +37 more
Jan 25, 2023

Carcinoma, Renal Cell Trial in Worldwide (Pembrolizumab, MK-4830, Belzutifan)

Recruiting
  • Carcinoma, Renal Cell
  • Pembrolizumab
  • +5 more
  • New Haven, Connecticut
  • +38 more
Jan 25, 2023

Advanced Solid Tumors Trial in Worldwide (Quavonlimab, Pembrolizumab, Pembrolizumab/Quavonlimab)

Active, not recruiting
  • Advanced Solid Tumors
  • Quavonlimab
  • +2 more
  • Gilbert, Arizona
  • +52 more
Aug 18, 2022

Uterine Cervical Tumors, Endometrial Tumors, Squamous Cell Carcinoma of Head and Neck Trial in Worldwide

Recruiting
  • Uterine Cervical Neoplasms
  • +10 more
  • Pembrolizumab/Vibostolimab Co-Formulation
  • +11 more
  • Anchorage, Alaska
  • +65 more
Jan 27, 2023

Hematological Malignancies Trial in Worldwide (Pembrolizumab/vibostolimab coformuation)

Recruiting
  • Hematological Malignancies
  • Pembrolizumab/vibostolimab coformuation
  • Duarte, California
  • +64 more
Jan 27, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +2 more
  • Los Angeles, California
  • +28 more
Aug 12, 2022

Lung Tumors, Non-Small-Cell Lung Carcinoma Trial in Worldwide (Pembrolizumab/Vibostolimab, Pembrolizumab)

Recruiting
  • Lung Neoplasms
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab/Vibostolimab
  • Pembrolizumab
  • Boca Raton, Florida
  • +146 more
Aug 10, 2022

Metastatic NSCLC Trial in Worldwide (Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin)

Recruiting
  • Metastatic Non-Small Cell Lung Cancer
  • Pembrolizumab/Vibostolimab
  • +6 more
  • Colorado Springs, Colorado
  • +134 more
Jan 27, 2023

Melanoma Trial in Nedlands, Haifa, Jerusalem (Pembrolizumab/Vibostolimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Pembrolizumab/Vibostolimab
  • Pembrolizumab
  • Nedlands, Western Australia, Australia
  • +2 more
Jan 31, 2023

Small Cell Lung Carcinoma Trial in Worldwide (Pembrolizumab/Vibostolimab Co-Formulation, Saline , Etoposide)

Recruiting
  • Small Cell Lung Carcinoma
  • Pembrolizumab/Vibostolimab Co-Formulation
  • +5 more
  • Los Angeles, California
  • +122 more
Jan 27, 2023

Renal Insufficiency,Chronic, Hiv, Therapeutic Agent Toxicity Trial in Arnhem, Amsterdam, Rotterdam (tenofovir alafenamide,

Unknown status
  • Renal Insufficiency,Chronic
  • +2 more
  • Arnhem, Gelderland, Netherlands
  • +4 more
Jan 27, 2020

New Antiretroviral Drugs on Children, Adolescents and Young

Completed
  • HIV Infections
  • Raltegravir (RAL)
  • +7 more
  • Birmingham, Alabama
  • +34 more
Aug 5, 2015

HIV-I Trial (TMC114; TMC41629)

Completed
  • HIV-I
  • TMC114; TMC41629
  • (no location specified)
Apr 26, 2010

Uncomplicated Malaria Trial in Allada (sulfadoxine-pyrimethamine, artemether-lumefantrine, amodiaquine-artesunate coformulation)

Completed
  • Uncomplicated Malaria
  • Allada, Benin
    Centre de santé
Apr 11, 2008